{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:32:20Z","timestamp":1786365140466,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-55363-6","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:53:50Z","timestamp":1780073630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-term intraocular pressure changes following intravitreal aflibercept 8\u00a0mg versus 2\u00a0mg in diabetic macular edema: a prospective observational study"],"prefix":"10.1038","volume":"16","author":[{"given":"Ken","family":"Hoshiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Sekiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Mukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Chiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"55363_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein, M., Schmitz-Valckenberg, S. & Chakravarthy, U. Age-related macular degeneration: a review. JAMA 331, 147\u2013157 (2024).","journal-title":"JAMA"},{"key":"55363_CR2","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.3390\/ijms24119591","volume":"24","author":"T Tatsumi","year":"2023","unstructured":"Tatsumi, T. Current treatments for diabetic macular edema. Int. J. Mol. Sci. 24, 9591 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"55363_CR3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/APO.0000000000000598","volume":"12","author":"F Romano","year":"2023","unstructured":"Romano, F. et al. Update on retinal vein occlusion. Asia Pac. J. Ophthalmol. (Phila. 12, 196\u2013210 (2023).","journal-title":"Asia Pac. J. Ophthalmol. (Phila"},{"key":"55363_CR4","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41433-020-0895-z","volume":"34","author":"AP Adamis","year":"2020","unstructured":"Adamis, A. P., Brittain, C. J., Dandekar, A. & Hopkins, J. J. Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. Eye (Lond. 34, 1966\u20131972 (2020).","journal-title":"Eye (Lond"},{"key":"55363_CR5","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier, J. S. et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 123, 2376\u20132385 (2016).","journal-title":"Ophthalmology"},{"key":"55363_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s10384-021-00820-0","volume":"65","author":"T Hirano","year":"2021","unstructured":"Hirano, T. et al. Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial. Jpn J. Ophthalmol. 65, 354\u2013362 (2021).","journal-title":"Jpn J. Ophthalmol."},{"key":"55363_CR7","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1038\/s41598-021-83811-y","volume":"11","author":"T Hirano","year":"2021","unstructured":"Hirano, T. et al. Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema. Sci. Rep. 11, 4488 (2021).","journal-title":"Sci. Rep."},{"key":"55363_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/IJG.0000000000001894","volume":"30","author":"AM Levin","year":"2021","unstructured":"Levin, A. M., Chaya, C. J., Kahook, M. Y. & Wirostko, B. M. Intraocular pressure elevation following intravitreal anti-VEGF injections: short- and long-term considerations. J. Glaucoma. 30, 1019\u20131026 (2021).","journal-title":"J. Glaucoma"},{"key":"55363_CR9","first-page":"402","volume":"4","author":"G Arikan","year":"2011","unstructured":"Arikan, G., Osman Saatci, A. & Hakan Oner, F. Immediate intraocular pressure rise after intravitreal injection of ranibizumab and two doses of triamcinolone acetonide. Int. J. Ophthalmol. 4, 402\u2013405 (2011).","journal-title":"Int. J. Ophthalmol."},{"key":"55363_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000446878","volume":"236","author":"H El Chehab","year":"2016","unstructured":"El Chehab, H., Agard, E., Russo, A., Boujnah, Y. & Dot, C. Intraocular pressure spikes after aflibercept intravitreal injections. Ophthalmologica 236, 43\u201347 (2016).","journal-title":"Ophthalmologica"},{"key":"55363_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.survophthal.2017.08.008","volume":"63","author":"P Bracha","year":"2018","unstructured":"Bracha, P., Moore, N. A., Ciulla, T. A., WuDunn, D. & Cantor, L. B. The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: a review. Surv. Ophthalmol. 63, 281\u2013295 (2018).","journal-title":"Surv. Ophthalmol."},{"key":"55363_CR12","doi-asserted-by":"publisher","first-page":"13248","DOI":"10.1038\/s41598-020-70269-7","volume":"10","author":"VA de Vries","year":"2020","unstructured":"de Vries, V. A., Bassil, F. L. & Ramdas, W. D. The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci. Rep. 10, 13248 (2020).","journal-title":"Sci. Rep."},{"key":"55363_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1755-3768.2009.01656.x","volume":"89","author":"H Kerimoglu","year":"2011","unstructured":"Kerimoglu, H., Ozturk, B. T., Bozkurt, B., Okka, M. & Okudan, S. Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol. 89, 138\u2013142 (2011).","journal-title":"Acta Ophthalmol."},{"key":"55363_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1167\/iovs.04-0162","volume":"46","author":"IG Pallikaris","year":"2005","unstructured":"Pallikaris, I. G., Kymionis, G. D., Ginis, H. S., Kounis, G. A. & Tsilimbaris, M. K. Ocular rigidity in living human eyes. Invest. Ophthalmol. Vis. Sci. 46, 409\u2013414 (2005).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"55363_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejpb.2021.06.001","volume":"166","author":"A Allmendinger","year":"2021","unstructured":"Allmendinger, A., Butt, Y. L. & Mueller, C. Intraocular pressure and injection forces during intravitreal injection into enucleated porcine eyes. Eur. J. Pharm. Biopharm. 166, 87\u201393 (2021).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"55363_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta, P. et al. Intravitreal aflibercept 8\u00a0mg in neovascular age-related macular degeneration (Pulsar): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 403, 1141\u20131152 (2024).","journal-title":"Lancet"},{"key":"55363_CR17","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown, D. M. et al. Intravitreal aflibercept 8\u00a0mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet 403, 1153\u20131163 (2024).","journal-title":"Lancet"},{"key":"55363_CR18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/bjo-2024-326053","volume":"109","author":"A Paris","year":"2025","unstructured":"Paris, A. et al. Short-term intraocular pressure changes after intravitreal aflibercept 2\u00a0mg, aflibercept 8\u00a0mg and faricimab: a prospective, comparative study. Br. J. Ophthalmol. 109, 600\u2013605 (2025).","journal-title":"Br. J. Ophthalmol."},{"key":"55363_CR19","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.3390\/jcm14144821","volume":"14","author":"M Yamamoto","year":"2025","unstructured":"Yamamoto, M. et al. Immediate and short-term intraocular pressure changes following intravitreal injection and associated factors. J. Clin. Med. 14, 4821 (2025).","journal-title":"J. Clin. Med."},{"key":"55363_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ophtha.2018.11.019","volume":"126","author":"A Hoguet","year":"2019","unstructured":"Hoguet, A. et al. The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: A report by the American Academy of Ophthalmology. Ophthalmology 126, 611\u2013622 (2019).","journal-title":"Ophthalmology"},{"key":"55363_CR21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jfo.2012.02.009","volume":"35","author":"H El Chehab","year":"2012","unstructured":"El Chehab, H. et al. [Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections]. J. Fr. Ophtalmol. 35, 614\u2013621 (2012).","journal-title":"J. Fr. Ophtalmol"},{"key":"55363_CR22","doi-asserted-by":"publisher","first-page":"589783","DOI":"10.2147\/OPTH.S589783","volume":"20","author":"K Itoh","year":"2026","unstructured":"Itoh, K. & Negishi, M. Measurement of acute intraocular pressure elevation immediately after intravitreal anti-VEGF injection and analysis of prefilled syringe accuracy. Clin. Ophthalmol. 20, 589783 (2026).","journal-title":"Clin. Ophthalmol."},{"key":"55363_CR23","doi-asserted-by":"publisher","first-page":"18136","DOI":"10.1038\/s41598-022-23039-6","volume":"12","author":"VLS Dingerkus","year":"2022","unstructured":"Dingerkus, V. L. S. et al. Incidence of severe rise in intraocular pressure after intravitreous injection of aflibercept with prefilled syringes. Sci. Rep. 12, 18136 (2022).","journal-title":"Sci. Rep."},{"key":"55363_CR24","doi-asserted-by":"publisher","first-page":"1295633","DOI":"10.3389\/fmed.2023.1295633","volume":"10","author":"JE Klaas","year":"2023","unstructured":"Klaas, J. E. et al. Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation. Front. Med. (Lausanne). 10, 1295633 (2023).","journal-title":"Front. Med. (Lausanne)"},{"key":"55363_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/1120672119836613","volume":"29","author":"E Uyar","year":"2019","unstructured":"Uyar, E., Ulas, F., Sahin, S. & Celebi, S. Major factors affecting intraocular pressure spike after intravitreal ranibizumab injection: vitreous reflux and its amount. Eur. J. Ophthalmol. 29, 361\u2013367 (2019).","journal-title":"Eur. J. Ophthalmol."},{"key":"55363_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12886-017-0417-3","volume":"17","author":"S Jeong","year":"2017","unstructured":"Jeong, S., Sagong, M. & Chang, W. Acute angle closure attack after an intravitreal bevacizumab injection for branch retinal vein occlusion: a case report. BMC Ophthalmol. 17, 25 (2017).","journal-title":"BMC Ophthalmol."},{"key":"55363_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5301\/ejo.5000241","volume":"23","author":"Z Alkin","year":"2013","unstructured":"Alkin, Z. et al. Changes in anterior segment morphology after intravitreal injection of bevacizumab and bevacizumab-triamcinolone acetate combination. Eur. J. Ophthalmol. 23, 504\u2013509 (2013).","journal-title":"Eur. J. Ophthalmol."},{"key":"55363_CR28","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/IJG.0b013e31819c4893","volume":"18","author":"M Gismondi","year":"2009","unstructured":"Gismondi, M., Salati, C., Salvetat, M. L., Zeppieri, M. & Brusini, P. Short-term effect of intravitreal injection of ranibizumab (Lucentis) on intraocular pressure. J. Glaucoma. 18, 658\u2013661 (2009).","journal-title":"J. Glaucoma"},{"key":"55363_CR29","doi-asserted-by":"publisher","first-page":"100001","DOI":"10.1016\/j.ajoint.2024.100001","volume":"1","author":"A Hibsh","year":"2024","unstructured":"Hibsh, A., Barak, A., Fleissig, E., Regenbogen, M. & Klein, A. Assessment of intraocular pressure changes following intravitreal injections of three anti-VEGF agents. AJO Int. 1, 100001 (2024).","journal-title":"AJO Int."},{"key":"55363_CR30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/pharmaceutics11080365","volume":"11","author":"L Garc\u00eda-Quintanilla","year":"2019","unstructured":"Garc\u00eda-Quintanilla, L. et al. Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration. Pharmaceutics 11, 365 (2019).","journal-title":"Pharmaceutics"},{"key":"55363_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10384-012-0194-8","volume":"57","author":"A Cacciamani","year":"2013","unstructured":"Cacciamani, A. et al. Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. Jpn J. Ophthalmol. 57, 63\u201367 (2013).","journal-title":"Jpn J. Ophthalmol."},{"key":"55363_CR32","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1600-0420.2007.00939.x","volume":"85","author":"K Kotliar","year":"2007","unstructured":"Kotliar, K. et al. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol. Scand. 85, 777\u2013781 (2007).","journal-title":"Acta Ophthalmol. Scand."},{"key":"55363_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/15569527.2012.696569","volume":"32","author":"A Goktas","year":"2013","unstructured":"Goktas, A., Goktas, S., Atas, M., Demircan, S. & Yurtsever, Y. Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure. Cutan. Ocul Toxicol. 32, 23\u201326 (2013).","journal-title":"Cutan. Ocul Toxicol."},{"key":"55363_CR34","doi-asserted-by":"publisher","first-page":"12246","DOI":"10.1038\/s41598-021-91832-w","volume":"11","author":"M Maruyama-Inoue","year":"2021","unstructured":"Maruyama-Inoue, M. et al. Incidence of elevated intraocular pressure after intravitreal injection in Japanese patients with age-related macular degeneration. Sci. Rep. 11, 12246 (2021).","journal-title":"Sci. Rep."},{"key":"55363_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jcjo.2014.11.004","volume":"50","author":"E Agard","year":"2015","unstructured":"Agard, E. et al. Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma. Can. J. Ophthalmol. 50, 127\u2013131 (2015).","journal-title":"Can. J. Ophthalmol."},{"key":"55363_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ophtha.2011.08.011","volume":"119","author":"QV Hoang","year":"2012","unstructured":"Hoang, Q. V. et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 119, 321\u2013326 (2012).","journal-title":"Ophthalmology"},{"key":"55363_CR37","first-page":"132","volume":"171","author":"G Krieglstein","year":"1975","unstructured":"Krieglstein, G. & Langham, M. E. Influence of body position on the intraocular pressure of normal and glaucomatous eyes. Ophthalmologica 171, 132\u2013145 (1975).","journal-title":"Ophthalmologica"},{"key":"55363_CR38","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.3390\/jcm11216234","volume":"11","author":"M De Bernardo","year":"2022","unstructured":"De Bernardo, M. et al. Intraocular pressure measurements in standing, sitting, and supine position: comparison between Tono-pen Avia and Icare pro tonometers. J. Clin. Med. 11, 6234 (2022).","journal-title":"J. Clin. Med."},{"key":"55363_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40662-021-00249-z","volume":"8","author":"S Nakakura","year":"2021","unstructured":"Nakakura, S. et al. Evaluation of rebound tonometer iCare IC200 as compared with IcarePRO and Goldmann applanation tonometer in patients with glaucoma. Eye Vis. 8, 25 (2021).","journal-title":"Eye Vis."},{"key":"55363_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12886-019-1236-5","volume":"19","author":"M Chen","year":"2019","unstructured":"Chen, M. et al. Comparability of three intraocular pressure measurement: iCare pro rebound, non-contact and Goldmann applanation tonometry in different IOP group. BMC Ophthalmol. 19, 225 (2019).","journal-title":"BMC Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55363-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55363-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55363-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:04:03Z","timestamp":1786363443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55363-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55363"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55363-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.H. has received personal fees from Novartis Pharma K.K., Bayer, Canon, Kowa Pharmaceutical, Senju Pharmaceutical, Chugai Pharmaceutical, and Santen Pharmaceutical. T.M. has received personal fees from Novartis Pharma K.K., Bayer, Canon, Kowa Pharmaceutical, Senju Pharmaceutical, Chugai Pharmaceutical, Kyowa Kirin, and Santen Pharmaceutical. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24656"}}